Stay updated with breaking news from Cingulate Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Shares of Skechers U.S.A., Inc. (NYSE:SKX) shares fell during Friday’s session after the company reported mixed fourth-quarter financial re...
KANSAS CITY, Kan., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (Cingulate), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build
Stimulants, amphetamines, and methylphenidates are currently the first-line treatment for moderate to severe attention-deficit/hyperactivity disorder (ADHD) across the seven major global markets; France, Germany, Italy, Spain, the UK, the US, and Japan.
Cingulate (NASDAQ:CING – Free Report) had its price objective boosted by HC Wainwright to $8.00 in a research note released on Friday morning, Benzinga reports. HC Wainwright currently has a buy rating on the stock. Several other analysts also recently commented on CING. Laidlaw downgraded shares of Cingulate from a buy rating to a hold […]
The CNN Money Fear and Greed index remained in the "Extreme Greed" zone on Thursday. U.S. stocks closed mostly higher on Thursday, with the S&P 500 ending the session just 0.3% down from its record closing level, notched on Jan. 3, 2022. Traders see a 74.1% chance that the Fed will cut rates by 25 basis points in March.